The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Mitochondrial Permeability Transition: A Molecular Lesion with Multiple Drug Targets
Open accessAbstract
Mitochondrial permeability transition, as the consequence of opening of a mitochondrial permeability transition pore (mPTP), is a cellular catastrophe. Initiating bioenergetic collapse and cell death, it has been implicated in the pathophysiology of major human diseases, including neuromuscular diseases of childhood, ischaemia-reperfusion injury, and age-related neurodegenerative disease. Opening of the mPTP represents a major therapeutic target, as it can be mitigated by a number of compounds. However, clinical studies have so far been disappointing. We therefore address the prospects and challenges faced in translating in vitro findings to clinical benefit. We review the role of mPTP opening in disease, discuss recent findings defining the putative structure of the mPTP, and explore strategies to identify novel, clinically useful mPTP inhibitors, highlighting key considerations in the drug discovery process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · cited 1×
“Forced proximity between the E3-ligase and exposed lysine residues on the bound target protein, drives ubiquitination and proteasomal targeting for degradation [104].”
BackgroundBaines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., et al. (2005) · Nature · doi:10.1038/nature03434 · Cited by 2,280 · cited 7×
“Furthermore, CypD inhibitors shift the threshold for mPTP opening to a higher Ca2+ load, but do not completely suppress PTP opening [27].”
BackgroundInfluentialNakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Yamagata, H., Inohara, H., Kubo, T., & Tsujimoto, Y. (2005) · Nature · doi:10.1038/nature03317 · Cited by 1,635 · cited 3×
“Genetic or pharmacological ablation of CypD increases the threshold for Ca2+- and ROS-induced mPTP opening [27, 28].”
BackgroundThe ADP/ATP translocator is not essential for the mitochondrial permeability transition pore
Kokoszka, J. E., Waymire, K. G., Levy, S. E., Sligh, J. E., Cai, J., Jones, D. P., MacGregor, G. R., & Wallace, D. C. (2004) · Nature · doi:10.1038/nature02229 · Cited by 1,086
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Schinzel, A. C., Takeuchi, O., Huang, Z., Fisher, J. K., Zhou, Z., Rubens, J., Hetz, C., Danial, N. N., Moskowitz, M. A., & Korsmeyer, S. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505294102 · Cited by 820 · cited 1×
“remarkable array of disease states in different tissues [27-34], although as yet, these data have failed to translate into clinical benefit (Box 2).”
Backgroundp53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis
Vaseva, A. V., Marchenko, N. D., Ji, K., Tsirka, S. E., Holzmann, S., & Moll, U. M. (2012) · Cell · doi:10.1016/j.cell.2012.05.014 · Cited by 740 · cited 1×
“Furthermore, regulatory, non-structural interactions implicate CypD as a signalling hub between multiple functionally distinct proteins and potential mPTP modulators, including p53 [109], complement C1Q binding protein (C1QBP) [110], amyloid beta (Aβ) [9] and mitochondrial chaperones [54].”
BackgroundCyclosporine before PCI in Patients with Acute Myocardial Infarction
Cung, T.-T., Morel, O., Cayla, G., Rioufol, G., Garcia-Dorado, D., Angoulvant, D., Bonnefoy-Cudraz, E., Guérin, P., Elbaz, M., Delarche, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505489 · Cited by 713
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Lebraud, H., Wright, D. J., Johnson, C. N., & Heightman, T. D. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00280 · Cited by 413 · cited 1×
“Significant work has been done since conception, including applying click chemistry to improve cellular permeability, solubility and pharmacokinetics (CLIPTACs) [105].”
MethodElrod, J. W., Wong, R., Mishra, S., Vagnozzi, R. J., Sakthievel, B., Goonasekera, S. A., Karch, J., Gabel, S., Farber, J., Force, T., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43171 · Cited by 384
Clarke, S. J., McStay, G. P., & Halestrap, A. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202191200 · Cited by 376
Karch, J., Kwong, J. Q., Burr, A. R., Sargent, M. A., Elrod, J. W., Peixoto, P. M., Martinez-Caballero, S., Osinska, H., Cheng, E. H.-Y., Robbins, J., et al. (2013) · eLife · doi:10.7554/elife.00772 · Cited by 290 · cited 1×
“Outer membrane components, the voltage-dependent anion channel (VDAC) [15] and BCL-2 family members BAK/BAX [20] have further been suggested to play a role as modulators of pore opening.”
BackgroundHe, J., Ford, H. C., Carroll, J., Ding, S., Fearnley, I. M., & Walker, J. E. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702357114 · Cited by 251
SPG7 Is an Essential and Conserved Component of the Mitochondrial Permeability Transition Pore
Shanmughapriya, S., Rajan, S., Hoffman, N. E., Higgins, A. M., Tomar, D., Nemani, N., Hines, K. J., Smith, D. J., Eguchi, A., Vallem, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.08.009 · Cited by 209
He, J., Carroll, J., Ding, S., Fearnley, I. M., & Walker, J. E. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711201114 · Cited by 182 · cited 4×
“have failed to validate each hypothesised candidate [21-24], although some are now understood to play potential regulatory roles [25, 26].”
BackgroundInfluentialKwong, J. Q., Davis, J., Baines, C. P., Sargent, M. A., Karch, J., Wang, X., Huang, T., & Molkentin, J. D. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.36 · Cited by 174 · cited 2×
“have failed to validate each hypothesised candidate [21-24], although some are now understood to play potential regulatory roles [25, 26].”
BackgroundWarne, J., Pryce, G., Hill, J. M., Shi, X., Lennerås, F., Puentes, F., Kip, M., Hilditch, L., Walker, P., Simone, M. I., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.700385 · Cited by 99 · cited 2×
“Indeed, the success of edaravone and data linking persistent mPTP opening as a key pathophysiological mechanism in cell death across multiple disease states, including neurodegenerative diseases [9, 34, 69, 78, 103] and muscular dystrophies [7, 11, 130], opens the door to targeting distinct clinical”
BackgroundSelf-citationHAX-1 regulates cyclophilin-D levels and mitochondria permeability transition pore in the heart
Lam, C. K., Zhao, W., Liu, G.-S., Cai, W.-F., Gardner, G., Adly, G., & Kranias, E. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508760112 · Cited by 80 · cited 1×
“Finally, CypD protein expression and activity may be tightly regulated through complex interactions with hematopoietic-substrate-1 associated protein X-1 (HAX-1) [53], and heat-shock protein-90 [54], further complicating therapeutic targeting.”
BackgroundZhou, W., Marinelli, F., Nief, C., & Faraldo-Gómez, J. D. (2017) · eLife · doi:10.7554/elife.23781 · Cited by 75
Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
Okada, M., Yamashita, S., Ueyama, H., Ishizaki, M., Maeda, Y., & Ando, Y. (2018) · eNeurologicalSci · doi:10.1016/j.ensci.2018.05.001 · Cited by 68 · cited 10×
“Loss of CypD conferred neuroprotection across models of neurological disease, including Alzheimer’s disease, MS and ALS.”
BackgroundInfluential
Cited by
Mitochondrial dysfunction: mechanisms and advances in therapy
Zong, Y., Li, H., Liao, P., Chen, L., Pan, Y., Zheng, Y., Zhang, C., Liu, D., Zheng, M., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01839-8 · Cited by 1,172
López-Otín, C., & Kroemer, G. (2021) · Cell · doi:10.1016/j.cell.2020.11.034 · Cited by 499
Regulation of Mitochondrial ATP Production: Ca2+ Signaling and Quality Control
Boyman, L., Karbowski, M., & Lederer, W. J. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.007 · Cited by 309
Heavy metals induced mitochondrial dysfunction in animals: Molecular mechanism of toxicity
Sun, Q., Li, Y., Shi, L., Hussain, R., Mehmood, K., Tang, Z., & Zhang, H. (2022) · Toxicology · doi:10.1016/j.tox.2022.153136 · Cited by 258
Jurcău, M. C., Andronie-Cioara, F. L., Jurcău, A., Marcu, F., Ţiț, D. M., Pașcalău, N., & Nistor-Cseppentö, D. C. (2022) · Antioxidants · doi:10.3390/antiox11112167 · Cited by 226
Metadata
- Authors
- Briston, T., Selwood, D. L., Szabadkai, G., & Duchen, M. R.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 40
- Issue
- 1
- Pages
- 50-70
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2904483354
- Cited by
- 184
- References
- 22
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.